ow dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy

Not Applicable

• Conditions: Proliferative diabetic retinopathy

• Registration Number: JPRN-UMIN000007482
• Lead Sponsor: Division of Ophthalmology, Department of Visual Sciences, Surugadai-Hospital, Nihon University.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-04-01
• Study Completion: 2013-09-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who had undergone intraocular surgery or retinal photocoagulation within 6 months before the study, and those who had undergone intravitreal injection of drugs or sub-Tenon injection of steroids within 6 months before the study were excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Preoperative vitreous VEGF concentration, Number of intraoperative coagulation spots, Number of reoperation caused by recurent postoperative hemorrhage, Post operative Visual acuity, operation time, Kind of tamponade after operation, Number of intrapoerative photocoagulation

Secondary Outcome Measures

Name	Time	Method
VEGF concentrations in vitreous, surgical time, frequencies of using gas and silicon oil temponade, number of intraoperative laser treatment, frequency of iatrogenic retinal breaks, postoperative (1 month) visual acuity, visual improvement.